GOVX

Geovax Labs Inc

0.7210

Aug 28 • 3:59 PM ET +0.0040 (0.56%)

0.6400

Aftermarket • 7:58 PM ET -0.0810 (-11.23%)

Healthcare Biotechnology USA Nano NASD

Aug 27, 2:01 PMWarrant inducement deal brings $3.65M cash infusion to GOVX

Peers: AIM APRE JAGX KAPA KPRX BCDA BIVI NEUP CALC CVM

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	5.31M
Enterprise Value	2.49M
Income	-20.43M
Sales	0.00M
Book/sh	0.24
Cash/sh	0.43
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	19
IPO	May 12, 1997

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.02
P/C	1.69
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.54
Current Ratio	1.54
Debt/Eq	0.18
LT Debt/Eq	0.10
Option/Short	No / Yes

EPS (ttm)	-13.93
EPS next Y	-2.85
EPS next Q	-1.20
EPS this Y	77.95%
EPS next Y	42.21%
EPS next 5Y	49.07%
EPS past 3/5Y	58.34% 51.11%
Sales past 3/5Y	- 6.42%
EPS Y/Y TTM	77.63%
Sales Y/Y TTM	-100.00%
EPS Q/Q	88.91%
Sales Q/Q	-100.00%
Earnings	Apr 30
EPS/Sales Surpr.	49.37% -

Insider Own	0.04%
Insider Trans	0.00%
Inst Own	11.94%
Inst Trans	6.99%
ROA	-408.80%
ROE	-891.59%
ROIC	-1058.19%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	3.38%
SMA50	-21.51%
SMA200	-74.84%
Trades

Shs Outstand	7.37M
Shs Float	7.37M
Short Float	2.47%
Short Ratio	0.24
Short Interest	0.18M
52W High	19.20 -96.25%
52W Low	0.59 22.20%
Volatility	15.83% 11.81%
ATR (14)	0.10
RSI (14)	46.20
Beta	3.67
Rel Volume	0.97
Avg Volume	766.67K
Volume	744,466

Perf Week	11.68%
Perf Month	2.62%
Perf Quarter	-65.00%
Perf Half Y	-54.94%
Perf YTD	-83.13%
Perf Year	-96.13%
Perf 3Y	-99.67%
Perf 5Y	-99.97%
Perf 10Y	-100.00%
Recom	1.00
Target Price	10.00
Prev Close	0.72
Price	0.72
Change %	0.56%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-19-26	Downgrade	D. Boral Capital	Buy → Hold
Apr-15-25	Reiterated	D. Boral Capital	Buy	$18 → $14
Apr-15-25	Reiterated	Alliance Global Partners	Buy	$15 → $8.50
Nov-11-24	Initiated	Alliance Global Partners	Buy	$15
Jul-16-24	Initiated	ROTH MKM	Buy	$20
Nov-19-20	Initiated	Maxim Group	Buy	$8

Aug-26-26 08:30AM	GeoVax Announces a Warrant Inducement Transaction (NewMediaWire)
Aug-25-26 08:37AM	GeoVax Advances GEO-MVA Toward Pivotal Phase 3 Study Implementation (NewMediaWire) -6.47%
Aug-24-26 10:43AM	GeoVax Initiates Global Health Outreach to WHO, Africa CDC and Other Agencies Regarding Ebola Vaccine Portfolio Amid Expanding Outbreak (NewMediaWire) +6.30%
08:37AM	GeoVax Applauds Clinical Validation of Combination Immunotherapy Strategies (NewMediaWire)
Aug-20-26 09:00AM	GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences Summit (NewMediaWire)
11:00AM	Loading…
Aug-13-26 11:00AM	GeoVax Highlights Capabilities Amid Congo's Expanding Ebola Outbreak (NewMediaWire)
Aug-11-26 09:00AM	GeoVax Highlights Gedeptin(R) Tumor-Priming Strategy as Immuno-Oncology Enters New Phase (NewMediaWire)
Aug-10-26 05:02PM	GeoVax targets Q4 phase 3 trial for MVA mpox vaccine with EMA expedited pathway (Proactive)
Aug-06-26 09:00AM	GeoVax Announces Completion of Key GEO-MVA Development Milestones, Positioning Program for Pivotal Phase 3 Clinical Study (NewMediaWire)
Aug-03-26 09:00AM	GeoVax Highlights Newly Published Independent Research Supporting Broader Filovirus Vaccine Strategies and Strategic Value of Its MVA-Based Vaccine Portfolio (NewMediaWire) +6.39%
Jul-27-26 04:00PM	GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update (NewMediaWire)
Jul-21-26 09:00AM	GeoVax Highlights Strategic Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy (NewMediaWire)
Jul-01-26 09:00AM	GeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine Readiness (NewMediaWire)
Jun-17-26 09:00AM	GeoVax Highlights Strategic Implications of Recent Gedeptin(R) Findings for Checkpoint-Resistant Cancers (NewMediaWire)
Jun-08-26 09:00AM	GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy Responses (NewMediaWire) -18.79%
09:00AM	Loading…
Jun-03-26 09:00AM	GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation (NewMediaWire)
Jun-01-26 09:15AM	GeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat Readiness (NewMediaWire) +7.28%
May-27-26 09:00AM	Registration Now Open for Tribe Public CEO Presentation and Q&A Webinar Event (NewMediaWire) -23.50%
May-26-26 11:45AM	Why Is GOVX Stock Falling Today? (Stocktwits)
07:30AM	GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R) (NewMediaWire)
May-20-26 10:00AM	GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms (NewMediaWire) +10.95%
May-18-26 02:30PM	GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats (NewMediaWire) +79.67%
12:46PM	GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules (NewMediaWire)
10:30AM	BC-Most Active Stocks (Associated Press)
May-14-26 04:00PM	GeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation Plans (NewMediaWire)
May-13-26 09:00AM	GeoVax Highlights Emerging Role of Gedeptin(R) in Combination Immunotherapy Strategies Targeting Immunologically Cold Tumors (NewMediaWire) -5.11%
May-07-26 08:00AM	GeoVax Announces a Warrant Inducement Transaction (NewMediaWire) +6.67%
May-06-26 10:00AM	GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging Pathway (NewMediaWire) +16.20%
Apr-29-26 09:00AM	GeoVax Advances Gedeptin(R) Toward Phase 2 Initiation and Strategic Partnership Opportunities (NewMediaWire)
Apr-27-26 09:00AM	GeoVax Highlights Gedeptin(R) as a Potential Immune-Sensitizing Platform Amid Rising Industry Investment in In Vivo Cancer Therapies (NewMediaWire)
04:07PM	Loading…
Apr-15-26 04:07PM	GeoVax Reports 2025 Year-End Financial Results and Provides Business Update (NewMediaWire)
Apr-14-26 09:00AM	GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine Market (NewMediaWire)
Apr-02-26 09:00AM	GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026 (NewMediaWire) -5.67%
Mar-31-26 02:33PM	GeoVax Announces a Warrant Inducement Transaction (NewMediaWire)
Mar-25-26 09:00AM	GeoVax Provides Update on GEO-MVA Program (NewMediaWire)
Mar-12-26 09:00AM	GeoVax Announces European Society of Medicine Publication Highlighting GEO-CM04S1 as a Next-Generation COVID-19 Vaccine for Immunocompromised Patients (NewMediaWire)
Mar-11-26 09:00AM	GeoVax Initiates Outreach Regarding Future Procurement of GEO-MVA Mpox/Smallpox Vaccine (NewMediaWire)
Feb-24-26 09:00AM	GeoVax Announces Oncology Advisory Board to Advance Gedeptin(R) Development Across Solid Tumors (NewMediaWire)
Feb-19-26 09:40AM	Shopify, eBay upgraded: Wall Street's top analyst calls (The Fly) +12.23%
Feb-18-26 09:00AM	GeoVax Secures Exclusive License for Gedeptin(R) + Immune Checkpoint Inhibitor Combination Technology (NewMediaWire) -12.03%
Feb-17-26 09:00AM	GeoVax Endorses Global Call to Sustain Mpox Response as Evidence Confirms Epidemic Is Far From Over (NewMediaWire) -5.95%
Feb-13-26 08:00AM	GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (NewMediaWire) -27.27%
Jan-20-26 09:00AM	GeoVax Highlights 2026 as a Pivotal Year for Progress (NewMediaWire) -6.69%
Jan-08-26 09:00AM	GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement (NewMediaWire) -9.23%
Jan-06-26 09:00AM	GeoVax Labs, Inc. to Review Progress and Strategic Priorities During Biotech Showcase 2026 and J.P. Morgan Healthcare Conference Week (NewMediaWire) +14.47%
Dec-19-25 09:24AM	GeoVax to Raise Approximately $3.2 Million of Gross Proceeds in Public Offering (NewMediaWire) -33.69%
Dec-18-25 01:00PM	GeoVax Announces Publication of Study Demonstrating Cross-Variant Protection Using the Multi-Antigen GEO-CM04S1 Vaccine (NewMediaWire)
09:00AM	GeoVax Receives Formal EMA Scientific Advice Supporting Pivotal Phase 3 Immunobridging Trial for GEO-MVA (NewMediaWire)
Dec-17-25 09:00AM	GeoVax Announces Completion of GEO-MVA Fill-Finish, Supporting Phase 3 Immunobridging Clinical Trial Start-Up in Early 2026 (NewMediaWire) -12.74%
Dec-16-25 09:00AM	GeoVax Receives U.S. Patent Office Notice of Allowance for Broad-Spectrum COVID-19 Vaccine Design (NewMediaWire) -13.99%
Dec-15-25 09:00AM	GeoVax Announces British Journal of Haematology Publication Highlighting Superior T-Cell Responses of GEO-CM04S1 in CLL Patients (NewMediaWire) -11.13%
Dec-11-25 09:00AM	GeoVax Addresses Identification of New Mpox Variant (NewMediaWire)
Dec-10-25 09:00AM	GeoVax Announces Addition of Renowned Global Experts to Its Scientific Advisory Board (NewMediaWire)
Dec-09-25 09:00AM	GeoVax Announces Issuance of U.S. Patent Covering Enhanced Therapeutic Use of Gedeptin(R) Gene Therapy (NewMediaWire)
Dec-08-25 09:00AM	GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin(R) in Recurrent Head & Neck Cancer (NewMediaWire) +9.33%
Nov-24-25 09:00AM	GeoVax to Present at the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference (NewMediaWire)
Nov-14-25 06:00PM	Geovax Labs Inc (GOVX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com) -9.11%
Nov-13-25 04:00PM	GeoVax Reports Third Quarter 2025 Financial Results and Provides Business Update (NewMediaWire) -5.80%
Nov-10-25 09:00AM	GeoVax Recognizes World Immunization Day: Advancing Innovation and Trust in Vaccination (NewMediaWire)
Nov-04-25 09:00AM	GeoVax to Report Third Quarter 2025 Financial Results and Provide Corporate Update on November 13, 2025 (NewMediaWire) -5.18%
Nov-03-25 09:00AM	GeoVax Announces Relocation of Corporate Headquarters and Laboratory Operations to Support Accelerated Growth and Pipeline Advancement (NewMediaWire)
Oct-30-25 01:00PM	BIO CEO Warns U.S. Could Lose Biotech Leadership Within Two Years; GeoVax Calls on Congress and Administration to Act Now (NewMediaWire)
Oct-29-25 09:00AM	GeoVax Connects IDSA Guidance on COVID-19 Vaccination for Immunocompromised Patients With Recent Clinical Data for GEO-CM04S1 (NewMediaWire) -7.81%
Oct-28-25 09:00AM	GeoVax Welcomes New IDSA Guidance Highlighting Need for Tailored COVID-19 Vaccines for Immunocompromised Patients (NewMediaWire)
Oct-20-25 10:30AM	GeoVax Highlights Urgent Need for Multisource Mpox Vaccine Supply Following California Clade 1 Cases (NewMediaWire) +8.16%
Oct-16-25 09:00AM	GeoVax Highlights Positive Interim Results for Multi-Antigen COVID-19 Vaccine in Immunocompromised Patients at World Vaccine Congress Europe 2025 (NewMediaWire) -5.80%
Oct-13-25 09:00AM	GeoVax Leadership to Participate in Key European Meetings to Advance Partnering Discussions (NewMediaWire)
Oct-09-25 09:00AM	GeoVax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2025 (NewMediaWire)
Oct-07-25 09:00AM	GeoVax to Participate in the 4th Annual ROTH Healthcare Opportunities Conference (NewMediaWire)
Oct-01-25 09:00AM	GeoVax to Sponsor the 2025 Dr. David Satcher Global Health Equity Summit (NewMediaWire) +13.93%
Sep-30-25 09:07AM	GeoVax Labs Announces $2.5 Million Registered Direct Offering (NewMediaWire) -24.79%
Sep-29-25 09:00AM	GeoVax Comments on U.S. America First Global Health Strategy and Highlights Company's Role in Advancing American Innovation, Pandemic Preparedness, and Global Health Security (NewMediaWire)
Sep-24-25 09:00AM	GeoVax Expands Gedeptin(R) Development to Additional Solid Tumor Indications (NewMediaWire)
Sep-22-25 09:00AM	GeoVax Reaffirms Commitment to Evidence-Based Vaccine Safety and Development of GEO-CM04S1 for Vulnerable Populations (NewMediaWire)
Sep-18-25 09:00AM	GeoVax to Present CM04S1 Clinical Progress at the Emerging Growth Conference (NewMediaWire)
Sep-15-25 09:00AM	GeoVax Showcases Positive Phase 2 Data for GEO-CM04S1 in CLL Patients at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Conference (NewMediaWire)
Sep-12-25 09:00AM	GeoVax Showcases Promising GEO-CM04S1 Clinical Data at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) Conference (NewMediaWire)
Sep-08-25 09:00AM	GeoVax to Present Multi-Antigen COVID-19 Vaccine Clinical Data at September International Scientific Conferences (NewMediaWire)
Sep-03-25 09:00AM	GeoVax to Present at the H.C. Wainwright 27th Annual Global Investment Conference (NewMediaWire)
Aug-20-25 12:00PM	GeoVax Labs (GOVX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +7.33%
09:00AM	GeoVax Announces Allowance of Patent Protecting Multi-Antigen COVID-19 Vaccine Constructs (NewMediaWire)
Aug-18-25 09:00AM	GeoVax to Present at the Emerging Growth Conference on August 20, 2025 (NewMediaWire)
Aug-07-25 09:00AM	GeoVax Comments on HHS mRNA Vaccine Rollback: Urges Full Embrace of MVA-Based Multi-Antigen Vaccine (NewMediaWire)
Jul-30-25 09:00AM	GeoVax Urges Immediate Action on Pandemic Preparedness as Biodefense Gaps Expose Fragile Supply Chains (NewMediaWire)
Jul-29-25 09:00AM	GeoVax Accelerates Development of GEO-MVA Vaccine Amid Expanding Global Mpox Crisis and Reaffirmed WHO Emergency Designation (NewMediaWire)
03:04AM	Geovax Labs Inc (GOVX) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
Jul-28-25 04:00PM	GeoVax Reports Second Quarter 2025 Financial Results and Provides Business Update (NewMediaWire) -6.33%
09:00AM	GeoVax Announces Research Program to Evaluate Needle-Free, Self-Administered GEO-MVA Vaccine Using Vaxxas Microarray Patch Technology (NewMediaWire)
Jul-24-25 09:00AM	GeoVax to Advance Gedeptin(R) Into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results (NewMediaWire)
Jul-22-25 09:00AM	GeoVax to Report Second Quarter 2025 Financial Results and Provide Corporate Update on July 28, 2025 (NewMediaWire)
Jul-21-25 09:00AM	GeoVax Highlights EMA Regulatory Milestone as Catalyst for Near-Term Revenue from GEO-MVA Mpox Vaccine (NewMediaWire) +7.19%
Jul-16-25 06:51PM	Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities (PR Newswire) +6.43%
09:00AM	GeoVax Highlights Growing Urgency for Diversified Mpox Vaccine Supply as Global Outbreaks Expand (NewMediaWire)
Jul-15-25 07:00AM	Presenting on Emerging Growth Conference 84 Day 1 on July 16; Register to live stream (GlobeNewswire)
Jul-14-25 09:00AM	GeoVax to Present at the Emerging Growth Conference on July 16, 2025 (NewMediaWire)
Jul-03-25 09:00AM	GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat (NewMediaWire)
Jul-02-25 09:30AM	GeoVax Responds to Growing Mpox Threat With Expedited EU Pathway and Platform Aligned to U.S. Biodefense Objectives (NewMediaWire)
Jul-01-25 08:30AM	GeoVax to Raise Approximately $6 Million of Gross Proceeds in Public Offering (NewMediaWire) -43.98%
Jun-25-25 08:00AM	GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection (NewMediaWire)
Jun-24-25 09:00AM	GeoVax Comments on FDA Approval of Keytruda(R) in Head and Neck Cancer, Underscoring Potential for Gedeptin(R) Combination Therapy (NewMediaWire)

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola-Zaire, Ebola-Sudan, Lassa, Marburg, Zika virus and malaria. The company was founded in June 1988 and is headquartered in Smyrna, GA.

ChairmanMr. David Alan Dodd

Chief Scientific OfficerDr. Mark J. Newman Ph.D.

M.D.Dr. Kelly T. McKee Jr.

Vice President of Quality Systems & ComplianceMr. Thomas O'Brien

Head of Process Development & Manufacturing OperationsMr. Jeffrey Welch

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GOVX

Geovax Labs Inc

Upgrade your Finviz experience